Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...DEL,N.J.,Nov.24/PRNewswire/--SpartaSystems,Inc.,th...prisequalityandcompliancesolutions,todayannouncedt...oductcompanyandtheparentcompanyforgloballyrecogniz...iseEnterpriseQualityManagementSystem(EQMS).Thecomp...streamlinequalityoperationsthatincludeCorrectivean...
(Date:11/24/2009)...N,China,Nov.24/PRNewswire-Asia/--HuifengBio-Pharma...eadingdeveloperandproducer,ofplantextractsandpharm...ceuticalandfoodproductioninXi,an,China,todayreport...reaseinrevenues. , Revenuesforthequarterended...r26%,from$3,534,623forthesamequarterin2008.Netinco...
(Date:11/24/2009)...E,N.J.,Nov.24/PRNewswire/--MAQUETCardiovascularLLC...uncedtodaythatithassignedaguaranteedtwo-yearcontra...ingorganizations,tobethesolesourceproviderofsurgic...rthetermsoftheagreement,whichrunsthroughOctober31,...rofbeatingheartdevicesanddisposablesuppliestotheme...
Breaking Medicine Technology:SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 2MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 3Dutch Top Institute Pharma Attracts International Interest 56710 1Dutch Top Institute Pharma Attracts International Interest 56710 2Cell Therapeutics Inc 28CTI 29 to Present at BioCenturys NewsMakers in the Biotech Industry Conference 13959 1Oxygen Biotherapeutics Inc Posts Latest Blog by CEO Chris Stern 56708 1
...Life-Changing for Stroke, Traumatic Brain Injury, ...s, MORGANTOWN, W.Va., Sept. 1 Scientists at the,...NI) have discovered that,Bryostatin -- and a relat...ed 24 hours after stroke can rescue and repair bra...mpared to current stroke treatments,that must be a...
...ar, Angioplasty and Stenting Matches Bypass Surger...with Complex Medical Condition, WASHINGTON, Sept....ages in at least three heart vessels will find goo...RDia trial, says The Society for,Cardiovascular An...indings,of the new study indicate that these patie...
Other Medicine Technology:Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 3
(Date:11/25/2009)...minimally-invasive procedures that provide patient...isk of sinusitis, or sinus infection, are being de...Snoring Institute. Techniques such as balloon sin...t having to remove any bone or tissue like traditi...akthroughs in treating sinus symptoms were feature...
(Date:11/25/2009)...fitPackages.com, California,s designated Premier P...awareness during the November 15 - December 31 Ann... to enroll in a zero-cost PPO Medicare Advantage p... are available through BenefitPackages.com to elig... Calabasas, CA (PRWEB) November 25, 2009 -- The s...
(Date:11/25/2009)...swire/-- AdamDreamHealer,s GlobalIntentionHealsPro...ysiologyofsomeoneatadistance.Over10,000participant...owasmonitoredbyaquantitative-EEG.Thedatawasanalyze...8inVancouver,B.C.Adaminitiatedtheworld,slargestint...eatedavideoclipofaspecificvisualizationtobeusedbya...
(Date:11/24/2009)... percent of radiation oncologists use advanced ima...hy (FDG-PET), magnetic resonance imaging (MRI), an...get delineation (to locate the tumor and other are...icle in the December issue of the Journal of the ....org ). , In defining the target, the radiation ...
(Date:11/24/2009)...t is linked to a significantly higher risk of stro...lished today in the British Medical Journal . , ... Health Organization,s Collaborating Centre for Nu...iversity Hospital in Coventry, UK, and the Europea...ertension based at the Department of Clinical and ...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO 2Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:High salt intake linked to strokes and cardiovascular disease 2
...ARRISBURG, Pa., Nov. 19 Secretary of Aging,Nora D...Medicare,beneficiaries to attend local enrollment ...dicare Part D prescription plan. The meetings, org...vember 15 and,will end December 31, with coverage ...
...ut patients can,t get enough CBD from just smoking...HealthDay News) -- A non-toxic, non-psychoactive c...astatic breast cancer, according to a new study by...static cancer," said lead researcher Sean D. McAll...
... New studies show that there is a demonstrable co...s or her likelihood of transmitting or getting HIV...r Disease Control (CDC) and others has been report... of HIV acquisition and transmission and adversely...
... GLENVIEW, Ill. The American Academy of Pain Medi...istration (DEA) ruling, which allows multiple pres...te. This DEA Final Ruling, Issuance of Multiple P... be a positive indication of recently improved com...
...ctress Molly Shannon Kicks Off the Return of the C...e This Holiday Season, NEW YORK, Nov. 19 Today t...of free, fully-staffed public restrooms,in New Yor...ceremonial "first flush" and ribbon cutting. To v...
...ERICHO, N.Y., Nov. 19 bioMETRX, Inc. (OTC,Bulleti...hnson has joined,the company as a Director. Ms. B...nt of Healthy,Living Channel and the Senior Vice P...l, Mall TV, Resorts and,Residence TV, iDrive and A...
Other Medicine News:Health News:Statewide Meetings Will Help Pennsylvanians to Choose Among Medicare Prescription Plans 2Health News:Cannabis Compound May Stop Metastatic Breast Cancer 2Health News:Cannabis Compound May Stop Metastatic Breast Cancer 3Health News:Unstable housing status increases the risk of HIV transmission 2Health News:AAPM statement on DEA ruling allowing multiple prescriptions for controlled substances 2Health News:Video: Charmin's Gift That Keeps on Giving! 2Health News:Wendy Borow-Johnson to Join bioMETRX Board of Directors 2Health News:Wendy Borow-Johnson to Join bioMETRX Board of Directors 3
Finntip 50
MBP 300E Multi-Channel
Luteinizing Hormone (LH) Enzyme Immunoassay Test Kit
Isletest™ -GAD Autoantibody EIA
Medicine Products: